抛物飞行微重力下干血斑采样用于咖啡因药代动力学研究的可行性
本研究在抛物飞行中验证干血斑(DBS)采样用于咖啡因及代谢物药代动力学的可行性。二十名志愿者参与,其中十七人完成飞行中采样,三人因晕动症未能采样。结果显示DBS采样安全、稳定、可行且接受度好,支持长期航天药理学研究。
要点
- 微重力下DBS采样安全可行,多数参与者可完成药代动力学采血。
- 咖啡因代谢比在飞行与地面间无显著差异,提示代谢适应有限。
- 雌激素避孕药女性代谢比低于其他参与者,与CYP1A2抑制一致。
核心结论
- DBS采样在微重力下安全、稳定、可行且接受度好,可为长期航天人体代谢适应研究提供支持。
研究设计与样本
- 在抛物飞行中先用合成血评估血样沉积于滤纸的分析前可行性,随后在另一抛物飞行活动中验证DBS采样。
- 二十名志愿者参与咖啡因及其代谢物对乙酰黄嘌呤的药代动力学研究,咖啡因洗脱>18小时后摄入咖啡(115 mg)、茶(30 mg)或黑巧克力(11 mg)。
- 在基线、失重期间及飞行后采集DBS样本,用液相色谱-串联质谱(LC-MS/MS)分析咖啡因和对乙酰黄嘌呤,并进行CYP1A2基因分型及代谢比(AUCPAX/AUCCAF)计算,另开展用户体验调查。
主要发现
- 十七名志愿者完成飞行中药代动力学研究,三人因晕动症无法采样;十九名参与者(十二男七女)完成药代动力学谱,其中六人重复研究。
- CYP1A2基因分型结果为八例超快代谢者、十一例中间代谢者和一例慢代谢者;四名使用雌激素避孕药(已知CYP1A2抑制剂)的女性被视为慢代谢者。
- 雌激素治疗女性平均代谢比为0.53(95%CI:0.35-0.71),其他人为1.19(95%CI:0.99-1.33);地面平均代谢比1.02(95%CI:0.81-1.23,n=15),飞行中1.10(95%CI:0.70-1.41,n=13),两者无显著差异。
临床怎么用
- DBS采样可作为微重力环境下治疗药物监测和药代动力学研究的可行采血方式。
- 解读咖啡因代谢比时需考虑CYP1A2基因型及雌激素避孕药等抑制剂的影响。
局限性
- 样本量有限,部分志愿者因晕动症未能完成采样。
- 研究采用咖啡因作为探针,结果外推至其他药物需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Therapeutic drug monitoring for astronauts faces limitations in conventional blood sampling and sample management onboard the international space station. Here, we explore the feasibility of dried blood spot (DBS) collection during parabolic flights (PF) to overcome these constraints. METHODS: We assessed the feasibility of blood deposition on blotting paper for preanalytical aspects in a PF using synthetic blood. Subsequently, DBS sampling validation was carried out in another PF campaign. Twenty volunteers participated in a pharmacokinetic study on caffeine and its metabolite, paraxanthine, conducted during parabolic flights. After >18 h caffeine washout, coffee (115 mg), tea (30 mg) or dark chocolate (11 mg) were ingested by the participants. DBS samples were collected at baseline, during weightlessness and post-flight. Caffeine and paraxanthine were analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Genotyping for cytochrome P450-1A2 (CYP1A2) was performed and a metabolic ratio by area under the curve for caffeine and paraxanthine (AUCPAX/AUCCAF) for CYP1A2 was determined. A user experience survey was also conducted. RESULTS: Full in-flight pharmacokinetic study was feasible in seventeen volunteers with three unable to perform the sampling due to motion sickness. Nineteen participants (twelve males and seven females) completed pharmacokinetic profiles, with repeated pharmacokinetic studies for six participants. CYP1A2 genotyping resulted in eight ultrarapid, eleven intermediate, and one poor metabolizer. Among the women, four were on oestrogen contraceptives, a known inhibitor of CYP1A2, and were considered as poor metabolizers. Expected differences in kinetic profiles, consistent with consumption habits, the ingested dose and the genotypic/phenotypic information, were observed. The mean caffeine AUC for coffee, tea and chocolate were 9419 ng.h.mL-1 (95% confidence interval [CI]: 6222-12 616, n = 10), 6917 ng.h.mL-1 (95% CI: 2729-11 105), n = 7) and 3039 ng.h.mL-1 (95% CI: 1614-4142, n = 12), respectively. The mean paraxanthine AUC were 10 566 ng.h.mL-1 (95% CI: 6242-14 890, n = 10), 4011 ng.h.mL-1 (95% CI: 2305-5716, n = 7) and 3638 ng.h.mL-1 (95% CI: 1589-40 859, n = 12), respectively. The mean metabolic ratio in oestrogen-treated women was 0.53 (95% CI: 0.35-0.71) compared to 1.19 (95% CI: 0.99-1.33) in others. The mean metabolic ratio was 1.02 (95% CI: 0.81-1.23, n = 15) on the ground and 1.10 (95% CI: 0.70-1.41, n = 13) during the parabolic flights, with no significant difference observed between the two conditions. Overall participants were satisfied with the usability of the method. CONCLUSIONS: DBS collection was safe, stable, feasible and well accepted in weightlessness. This method would offer valuable insights into human metabolism adaptation during long-term spaceflight, addressing space pharmacology challenges.
引用
- Derobertmasure A, Toh LS, Verstuyft C, et al. Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns. Br J Clin Pharmacol. 2024. PMID: 39473131. doi:10.1111/bcp.16320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。